| Abstract | Eight patients with active ulcerative colitis (UC), refractory to usual combination medical therapy, were treated with a single i.v. dose of chimeric monoclonal antibody to recombinant human tumor necrosis factor alpha; many of these patients were scheduled for surgical colectomy because of their active disease. All patients responded extremely well to a single 5 mg/kg infusion of infliximab, with marked improvement after the infusion clinically, colonoscopically, and histologically on colonic biopsy. There were no significant complications or side effects; mean duration of remission has not been determined because none of the patients have relapsed. Infliximab appears to be a potent agent for inducing remission in refractory patients with ulcerative colitis. |
| Authors | W Y Chey, A Hussain, C Ryan, G D Potter, A Shah
(Affiliation: Konar Center for Digestive and Liver Diseases, Rochester, New York, USA.)
|
| Journal | The American journal of gastroenterology
(Am J Gastroenterol)
Vol. 96
Issue 8
Pg. 2373-81
(Aug 2001)
ISSN: 0002-9270 United States |
| PMID | 11513177
(Publication Type: Case Reports, Journal Article)
|
| Chemical References |
- Antibodies, Monoclonal
- Gastrointestinal Agents
- infliximab
|
| Topics |
- Adult
- Aged
- Antibodies, Monoclonal
(administration & dosage, therapeutic use)
- Colitis, Ulcerative
(drug therapy, pathology)
- Colonoscopy
- Female
- Gastrointestinal Agents
(administration & dosage, therapeutic use)
- Humans
- Infusions, Intravenous
- Male
- Middle Aged
- Statistics, Nonparametric
- Treatment Outcome
|
